Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lymphoma
Biotech
Regeneron does 180 on 2seventy lymphoma CAR-T
Regeneron has given up on a CAR-T candidate acquired from 2seventybio last year, before it finished a phase 1/2 lymphoma study.
James Waldron
Oct 23, 2025 10:57am
Innate says lymphoma data shows anti-KIR3DL2 antibody’s promise
May 23, 2025 5:13am
Galapagos drops one CD19 CAR-T to focus on 'flagship' program
Feb 13, 2025 8:00am
RTW-built biotech's $520M deal for InnoCare, Keymed bispecific
Jan 21, 2025 4:32am
Cash-strapped Viracta ends phase 2 study of lead cancer drug
Jan 2, 2025 7:41am
Nkarta continues pivot to lupus by shelving lymphoma program
Nov 8, 2024 8:55am
